1 / 46

Epidemiology

Epidemiology. Definition Biology. The “Triple Negative” Breast Cancer. Estrogen Receptor ( ER ) negative Progesterone receptor ( PR ) negative Her2neu ( HER2 ) negative. ER/PR/HER2 -. “Basal-Like” . Clinical features.

cloris
Download Presentation

Epidemiology

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Epidemiology

  2. DefinitionBiology

  3. The “Triple Negative” Breast Cancer Estrogen Receptor (ER) negative Progesterone receptor (PR) negative Her2neu (HER2) negative ER/PR/HER2 - “Basal-Like”

  4. Clinical features

  5. “Triple-Negative” Breast Cancer: Clinical Features and Patterns of Recurrence • HBBC database (1987-1997) • 1601 (80%) of patients had details on hormone receptors/HER2 and were eligible for the study • 180 (12%) of the 1601 patients were defined as “triple negative” breast cancers • Mean follow up was 8.1 years Dent, R. et al. Clin Cancer Res 2007

  6. Characteristics of “Triple Negative” vs. Other Breast Cancers * p values were calculated with the use of the chi-square test Dent, R. et al. Clin Cancer Res 2007

  7. Tumor Size by Nodal Status according to “Basal-Like” Group * p values were calculated with the use of the chi-square test Dent, R. et al. Clin Cancer Res 2007

  8. “Triple-negative” (61 of 180) Other (290 of 1421) 0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 Distant Recurrence 1.0 0.9 0.8 0.7 0.6 0.5 Probability of being recurrence-free p<0.0001 (log-Rank test) 0.4 0.3 0.2 0.1 0.0 Years after diagnosis Dent, R. et al. Clin Cancer Res 2007;13:4429-4434

  9. “Triple-negative” (62 of 180) Other (261 of 1420) 0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 Overall Survival 1.0 0.9 0.8 0.7 0.6 0.5 Probability of survival p<0.0001 (log-Rank test) 0.4 0.3 0.2 0.1 0.0 Years after diagnosis Dent, R. et al. Clin Cancer Res 2007;13:4429-4434

  10. X² statistic 42.78 p  0.0003 Non-random distribution Subtype Smid et al, Cancer Res, in press

  11. Patterns of Metastatic Spread • More likely to spread to brain, lung and possibly liver and less likely to spread to bone and soft tissues • Tsuda et al. 2000 Am J of Surgical Pathology • Rodriguez-Pinilla et al. Clinical Cancer Research 2006 • Fulford et al. Breast Cancer Research and Treatment 2007 • Hicks et al. 2006 Am J of Surgical Pathology • More likely to present with visceral metastases versus bone metastases as first site of metastases • 70% vs 37%, p < 0.001 (Dent et al. SABCS 2007)

  12. Median Time from Distant Relapse to Death “Triple Negative” Breast CA 9 months Other Breast CA 22 months Dent R, Trudeau M, Pritchard K, Hana W, Narod S. et al. Clinical Cancer Res 2007

  13. Treatment

  14. Response of Brca1/p53Mammary Tumors to Doxorubicin or Cisplatin/Carboplatin in vivo

  15. Characteristics of retrieved studies - I Gennari et al, JNCI 2008

  16. Characteristics of studies - II Gennari et al, JNCI 2008

  17. Adjuvant Anthracyclines and HER2:Disease Free Survival Anthra better Non anthra better Study HER2 status HR (95% CI) + 0.60 (0.44 to 0.82) NSABP B11 - 0.96 (0.75 to 1.23) + 0.84 (0.65 to 1.08) NSABP B15 - 1.02 (0.86 to 1.20) + 0.65 (0.34 to 1.26) Belgian - 1.35 (0.93 to 1.97) + 0.83 (0.46 to 1.49) Milan - 1.22 (0.91 to 1.64) + 0.75 (0.53 to 1.06) DBCG 89D - 0.79 (0.60 to 1.05) + 0.52 (0.34 to 0.80) NCIC MA5 - 0.91 (0.71 to 1.17) Overall 0.90 (0.82 to 0.98) + 0.71 (0.61 to 0.83) HER2 specific - 1.00 (0.90 to 1.11) 0.00 0.50 1.00 1.50 2.00 Test for interaction: 2 13.7, p< .001 Gennari A. et al. JNCI 2008

  18. Adjuvant Anthracyclines and HER2 :Overall Survival Anthra better Non anthra better Study HER2 status HR (95% CI) + 0.66 (0.42 to 1.01) NSABP B11 - 0.90 (0.69 to 1.18) + 0.82 (0.63 to 1.06) NSABP B15 - 1.07 (0.88 to 1.30) + 0.85 (0.27 to 2.69) GUN - 1.64 (0.85 to 3.15) + 0.61 (0.32 to1.16) Milan - 1.26 (0.89 to 1.79) + 0.73 (0.50 to 1.05) DBCG 89D - 0.82 (0.59 to 1.13) + 0.65 (0.42 to 1.01) NCIC MA5 - 1.06 (0.80 to1.40) + 0.71 (0.32 to 1.55) GOIRC - 1.25 (0.58 to 2.67) Overall 0.91 (0.79 to 1.04) + 0.73 (0.62 to 0.85) HER2 specific - 1.03 (0.92 to 1.16) 0.00 0.50 1.00 1.50 2.00 2.50 3.00 3.50 Test for interaction: 2 12.6, p< .001 Gennari A. et al. JNCI 2008

  19. Efficacy summary • Risk of relapse 29% HR 0.71 (0.61-0.83) • Risk of death 27% HR 0.73 (0.62-0.85) HER2 negative HER2 positive Risk of relapse anthra ≈ non anthra HR 1.00 (0.90-1.11) Risk of death anthra ≈ non anthra HR 1.03 (0.92-1.16) p <0.001 p <0.001 Gennari et al, JNCI 2008

  20. Highly hormon-sensitive Moderately hormon-sensitive HER-2 amplified Triple negative

  21. Pathological Complete Response to Chemotherapy Differs by Subtipes

  22. Neoadjuvant Chemotherapy in Triple Negative Patients. MD Anderson Experience • The largest date set available (1118 pts) 23% TNBC, pCR 15% Liedtke, M. et al. J Clin Oncol; aheadof print on Febr 4, 2008

  23. Neoadjuvant Chemotherapy in TNBCSurvival by Pathological Response Liedtke, M. et al. J Clin Oncol; aheadof print on Febr 4, 2008

  24. Ixabepilone + Capecitabine N = 375 Metastaticbreast cancer N = 752 Capecitabine N = 377 Ixabepilone+Capecitabine a Phase III Trial Previous Anthra Taxane Resistant Vahdat LT et al: ASCO2007

  25. 1.0 0.8 Ixabepilone + Capecitabine Median 95 % Cl 0.6 Proportion Progression Free 5.8 mo 4.2 mo (5.5 - 7.0) (3.8 - 4.5) 0.4 HR: 0.75 (0.64-0.88) p = 0.0003 0.2 Capecitabine 0.0 0 4 8 12 16 20 24 28 32 36 Months Ixabepilone+Capecitabine a Phase III Trial Vahdat LT et al: ASCO2007

  26. Ixabepilone+Capecitabine a Phase III Trial Rugo et al: SABCS 2007

  27. Perspectives

  28. Basal-like Breast Cancer and BRCA1 = BRCA1+ Sorlie T et al. PNAS 03

More Related